Associated Papers
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.
Garmezy B et al.
Cancer Research Communications, 2024
38602417 (PubMed )
Supplement: crc-24-0137-s07.pdf
Select a paper to view details